PAT supplement 2011
Posted: 15 December 2011 | European Pharmaceutical Review | No comments yet
In this PAT supplement: The historical development of the FDA’s PAT initiative and its present course; Implementation of modelling approaches in the QbD framework: Examples from the Novartis experience; Challenges in development and implementation of spectroscopic techniques as PAT Analysers…
- The historical development of the FDA’s PAT initiative and its present course
(Terry McMahon, PAI Partners) - Implementation of modelling approaches in the QbD framework: Examples from the Novartis experience
(Dr. Marianna Machin, Dr. Lorenz Liesum and Dr. Antonio Peinado, Novartis Pharma AG) - Challenges in development and implementation of spectroscopic techniques as PAT Analysers
(Ravindra Dhumal and Tim Gough, Centre for Pharmaceutical Engineering Science, University of Bradford)
This PAT supplement is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- bi-monthly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Click here to Subscribe today Login here
Issue
Related topics
Related organisations
ABB, Bruker, FOSS NIRSystems, Novartis Pharma AG, PAI Partners, Sartorius, University of Bradford
Related people
Dr. Antonio Peinado, Dr. Lorenz Liesum, Dr. Marianna Machin, Ravindra Dhumal, Terry McMahon, Tim Gough
